Yufeng Huang

Yufeng Huang, MD, PhD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine

Divisions: Nephrology & Hypertension

Academic Office Information

yufeng.huang@hsc.utah.edu

Yufeng Huang, MD, Ph.D, is a research professor in the Department of Internal Medicine, Division of Nephrology at the University of Utah School of Medicine. As a basic and translational researcher, her research focuses on understanding the molecular mechanisms that drive kidney fibrosis and identifying new therapeutic strategies to slow or prevent CKD progression.

Huang received her medical degree and completed her residence at the Jiangsu University in China. She continuously completed her fellowship in Nephrology and received her Ph.D. degree at the Fudan University, Shanghai Medical College in China.

Research Statement

My laboratory investigates the molecular mechanisms driving kidney fibrosis—particularly the roles of HuR, EphB2 signaling, and NNMT/cGMP pathways—and develops targeted therapeutic strategies to prevent the progression of chronic kidney disease.

Education History

Professional Medical Zhenjiang Medical College, Jiangsu University
 MD
Internship Zhenjiang Medical College
 Intern
Residency Zhenjiang Medical College Hospital, Jiangsu University
 Resident
Fellowship Shanghai Medical College, Fudan University
 Fellow
Doctoral Training Fudan University Shanghai Medical College
 PhD
Postdoctoral Fellowship University of Utah School of Medicine
 Postdoctoral Fellow

Selected Publications

Journal Article

  1. Liu S, Huang Z, Tang A, Wu X, Aube J, Xu L, Xing C and Huang (2020). Inhibition of RNA-binding protein HuR reduces glomerulosclerosis in experimental nephritis. Clinical science (London, England, 134, 1433-1448.
  2. Tian M, Carroll LS, Tang L, Uehara H, Westenfelder C, Ambati BK, and Huang Y (2020). Systemic AAV10.COMP-Ang1 rescues renal glomeruli and pancreatic islets in type 2 diabetic mice. BMJ open diabetes research & care, 8(1), e000882.
  3. Zhou G., Wu J., Gu C.,Wang B, Abel E.D., Cheung A.K., and Huang (2018). Prorenin independently causes hypertension and renal and cardiac fibrosis in cyp1a1 prorenin transgenic rats. Clinical science (London, England, 132, 1345-1363.
  4. Zhang Y, Hansson KM, Liu T, Magnell K, Huang Y, Carlson NG, Kishore BK (2018). Genetic Deletion of ADP-activated P2Y12 Receptor Ameliorates Lithium-induced Nephrogenic Diabetes Insipidus in Mice. Acta physiologica (Oxford, England), 225, e13191.
  5. Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, Geschwindner S, Aagaard A, Granqvist AB, Jaisser F, Huang Y, Granberg KL, Jansson-Lofmark R, Hartleib-Geschwindner J (2018). Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PloS one, 13(2), E0193380.
  6. Conlin CC, Huang Y, Gordon BAJ, Zhang JL (2018). Quantitative characterization of glomerular fibrosis with magnetic resonance imaging. A feasibility study in a rat glomerulonephritis model. American journal of physiology. Renal physiology, 314, F747-F752.
  7. Tian M, Tang L, Wu Y, Beddhu S, Huang (2018). Adiponectin attenuates kidney injury and fibrosis in Deoxycorticosterone Acetate-Salt and Angiotensin II-induced CKD mice. American journal of physiology. Renal physiology, (315), F558-F571.
  8. Conlin C.C., Oesingmann N., Bolster Jr B. Huang Y., Lee V.S., and Zhang J.L (2017). Renal plasma flow (RPF) measured with multiple-inversion-time arterial spin labeling (ASL) and tracer kinetic analysis: Validation against a dynamic contrast enhancement method. Magnetic resonance imaging, 37, 51-55.
  9. Tang L, Wu Y, Tian M, Sjostrom CD, Johansson U, Peng XR, Smith DM and Huang Y (2017). Dapagliflozin slows the progression of the renal and liver fiboriss associated with type 2 diabetes. American journal of physiology. Endocrinology and metabolism, 313(5), E563-E576.
  10. Hwang J, Huang Y, Burwell TJ, Peterson NC, Connor J, Weiss SJ, Yu SM, Li Y (2017). In situ imaging of tissue remodeling with collagen hybridizing peptides. ACS nano, 11, 9825-9835.
  11. Klein J, Ramirez-Torres A, Ericsson A, Huang Y, Breuil B, Siwy J, Mischak H, Peng XR, Bascands JL, Schanstra JP (2016). Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney international, 90, 1045-1055.
  12. Conlin C.C., Oesingmann N., Bolster Jr B., Huang Y., Lee V.S., Zhang J. (2016). Renal plasma flow (RPF) measured with multiple-inversion-time arterial spin labeling (ASL) and tracer kinetic analysis: Validation against a dynamic contrast enhancement method. Magnetic resonance imaging, (37), 51-55.
  13. Zhou G, Johansson U, Peng XR, Bamberg K, Huang Y (2016). An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. American journal of translational research, 8(3), 1339-54.
  14. Beddhu S, Filipowicz R, Wang B, Wei G, Cheng X, Roy A.C, Duvall S., Farrukh H, Habib A, Bjhordahl T, Simmons D, Munger M, Stoddard G, Kohan D, Greene T and Huang (2016). A randomized controlled trial of the effects of febuxostat therapy on adiokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Canadian journal of kidney health and disease, 3, 1-11.
  15. Gu C, Zhang J, Noble NA, Peng XR, Huang Y (2016). An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease. American journal of physiology. Renal physiology, 311, F852- F863.
  16. Zhou G, Liu X, Cheung AK, Huang (2015). Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?. American journal of translational research, 7(5), 825-40.
  17. Zhang J, Gu C, Lawrence DA, Cheung AK and Huang Y (2014). A PAI-1 mutant retards diabetic nephropathy in db/db mice through protecting podocytes. Experimental physiology, 99, 802-815.
  18. Guo X, Zhou G, Guo M, Cheung AK, Huang Y and Beddhu S (2014). Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II. Physiological research, 2, e00230.
  19. Gu C, Noble NA, Border WA, Cheung AK and Huang Y (2014). Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocyte. Journal of the renin-angiotensin-aldosterone system, 15, 177-189.
  20. Zhou G, Cheung AK, Liu X and Huang Y (2013). Valsartan slows the progression of diabetic nephropathy in db/db mice via reduction in podocyte injury and renal oxidative stress and inflammation. Clinical science (London, England, 126, 707-720.
  21. Zhang J, Wu J, Gu C, Noble NA, Border WA and Huang Y (2012). Receptor-mediated non-proteolytic activation of prorenin and induction of TGFß1 and PAI-1 expression in renal mesangial cells. American journal of physiology. Renal physiology, 303, F11-20.
  22. Zhang J, Gu C, Noble NA, Border WA and Huang (2011). Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. American journal of physiology. Renal physiology, 301, F723-732.
  23. Zhang J, Noble NA, Border WA and Huang Y (2010). infusion of angiotensin-(1-7) reduces glomerulosclerosis in anti-thy 1 glomerulonephritis. American journal of physiology. Renal physiology, 298, F579-588.
  24. Huang Y, Border WA, Lawrence DA, Noble NA (2009). Mechanisms underlying the anti-fibrotic properties of non-inhibitory PAI-1 (PAI-1R) in experimental nephritis. American journal of physiology. Renal physiology, 297, F1045-1054.
  25. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA and Noble NA (2008). A non-inhibitory PAI-1 retards the progression of diabetic nephropathy in db/db mice. Journal of the American Society of Nephrology, 2008(86), 329-336.
  26. Ge Y, Huang Y, Kohan DE (2008). Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure. Canadian journal of physiology and pharmacology, 2008(86), 329-336.
  27. Zhang J, Noble NA, Border WA and Huang Y (corresponding author (2008). Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. American journal of physiology. Endocrinology and metabolism, 295, E810-E819.
  28. Huang W, Xu C, Kahng K, Noble NA, Border WA and Huang Y (corresponding author) (2008). Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. 2008(294), F1287-1295.
  29. Huang Y, Noble NA, Zhang J, Xu C, Border W (2007). Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney international, 72(1), 45-52.
  30. Huang Y, Border WA, Lawrence DA, Noble NA (2006). Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney international, 70(3), 515.
  31. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA and Border W (2006). Renin increases mesangial cell transforming growth factor-ß1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney international, 69(1), 105.
  32. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble N (2004). Combining TGFß inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney international, 66, 1774.
  33. Li ZP, Xu X, Huang YF, Zhu JF, Wang XJ, Hu HH, He Z (2003). Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor for occurrence of diabetic retinopathy (Chinese). [Zhonghua yan ke za zhi] Chinese journal of ophthalmology, 39(6), 352-6.
  34. Xu X, Li Z, Luo D, Huang Y, Zhu J, Wang X, Hu H, Patrick C (2003). Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 241(1), 56-62.
  35. Huang Y, Haraguchi M, Lawrence DA, Border WA, Noble N (2003). A mutant, non-inhibitory plasminogen activator inhibitor-type 1 (PAI-1) decreases matrix accumulation in experimental glomerulonephritis. The Journal of clinical investigation, 112, 337-388.
  36. Yu L, Border WA, Huang Y, Noble N (2003). TGFß isoforms and renal fibrogenesis. Kidney international, 64, 844-856.
  37. Haraguchi M, Border WA, Huang Y, Noble N (2001). t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney international, 59, 2146-2155.
  38. Huang Y, Shanyan L, Jianghua (1998). Gene expression of receptor for advanced glycation end products and its modulation by Aminoguanidine in diabetic kidney tissue. Chinese medical journal, 111 (8), 698.

Review

  1. Huang Y, Border WA, Noble N (2007). Functional Renin Receptors in Renal Mesangial Cells. Current hypertension reports, 9(2), 133-139.
  2. Huang Y, Noble N (2007). PAI-1 as a Target in Kidney Disease. Current drug targets, 8(9), 1007-15.

Editorial

  1. Huang Y, Border WA and Noble N (2006). Perspectives on blockade of TGF-ß overexpression. Kidney international, 69(10), 1713.
  2. Yufeng Huang, Nancy A. Nobl (2005). An unexpected role of plasminogen activator inhibitor-type 1 (PAI-1) in renal fibrosis. Kidney international, 67, 2502.